Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02207608
Recruitment Status : Completed
First Posted : August 4, 2014
Results First Posted : May 28, 2015
Last Update Posted : May 28, 2015
Sponsor:
Information provided by (Responsible Party):
Enrico Finazzi Agro, University of Rome Tor Vergata

Brief Summary:
The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.

Condition or disease Intervention/treatment Phase
Poisoning by BCG Vaccine Drug: Hyaluronic Acid Drug: BCG (Immucist®) Phase 2

Detailed Description:

Bacillus Calmette-Guérin (BCG) is considered the most effective treatment to increase disease-free interval and reduce progression of non-muscle invasive bladder cancer (NMIBC) [1]. Although considered safe, BCG can produce both local and systemic side effects leading to treatment discontinuation or interruption. The most common local side-effects of BCG intravesical instillations include cystitis, characterized by irritative voiding symptoms and hematuria, which occur in approximately 75% of all patients. More rarely, serious local adverse events as a result of BCG infection, such as symptomatic granulomatous prostatitis and epididymo-orchitis, might occur and require permanent discontinuation of BCG treatment. Systemic side-effects include flu-like symptoms, such as general malaise and fever, occuring in approximately 40% of patients. A high persistent fever might be related to BCG infection or sepsis. Local and systemic side-effects might lead to discontinue intravesical BCG treatment in approximately 20% of patients [2]. Up to 54% of the patients undergoing intravesical therapy with chemotherapeutic agents to treat superficial bladder tumours can be affected by nonbacterial cystitis [3].

Several solutions have been proposed to reduce the occurrence of side effects from BCG with the aim to limit BCG discontinuation and the concomitant discomfort during endovesical treatment. Some Authors have proposed to avoid BCG administration in case of TUR within previous 2 weeks, traumatic catheterization, macroscopic hematuria, urethral stenosis, active tuberculosis, prior Bacillus Calmette-Guérin sepsis, immuno-suppression or urinary tract infection [4]. Other procedures include the prophylactic administration of isoniazid [5] or ofloxacin [6,7] or usually involve BCG dose reductions [8]. In common practice antimicrobials, anticholinergics, anaesthetics and analgesics are often used to relieve patients' symptoms.

Glycosaminoglycan (GAG) substitution therapy is an emerging treatment of Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) and response rates between 30% and 80% have been described with intravesical administration of various GAGs (hyaluronic acid, pentosan polysulfate, heparin, chondroitin sulfate, and dimethyl sulfoxide) [9,10]. Few papers report the results of GAG substitution therapy in the treatment of radiation and chemical cystitis [9,10]. To our knowledge, to date, only two papers have described GAG use in the treatment of BCG local side effects; this papers show very good results, with significant reduction of lower urinary tract symptoms after intravesical administration of HA [11,12].

Aim of the present randomized pilot study was to evaluate if the sequential administration of HA and BCG could be safe in prevention of early recurrence and progression of bladder tumor, and safe in reduction of local side-effects in patients with high risk NMIBC.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects
Study Start Date : September 2011
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: BCG alone (Immucist®)
Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
Drug: BCG (Immucist®)
Usual BCG treatment
Other Name: BCG

Experimental: Hyaluronic acid
Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
Drug: Hyaluronic Acid
Add hyaluronic acid to BCG Treatment
Other Name: Cystistat (Mylan, Pittsburgh, PA, U.S.A.)

Drug: BCG (Immucist®)
Usual BCG treatment
Other Name: BCG




Primary Outcome Measures :
  1. Visual Analogue Scale for Pain [ Time Frame: Before and after six weeks of treatment (end of induction course) ]
    1 to 10 scale (1 minimum pain perceivable; 10 unbearable pain, as perceived by the patient)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven non-muscle invasive bladder cancer;
  • Indication to intravesical instillation of BCG according to EAU guidelines;
  • Age > 18 years;
  • Willingness, to participate to the study;
  • Written informed consent.

Exclusion Criteria:

  • Previous or ongoing BCG or different intravesical instillations;
  • Urinary tract infections (UTI) or other known pathologies of the lower urinary tract;
  • Indication for a radical cystectomy;
  • Severe systemic disorders, including neurological pathologies, kidney, liver or heart failure;
  • Contraindications to BCG use.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Enrico Finazzi Agro, Associate Professor, University of Rome Tor Vergata
ClinicalTrials.gov Identifier: NCT02207608     History of Changes
Other Study ID Numbers: EA-1
First Posted: August 4, 2014    Key Record Dates
Results First Posted: May 28, 2015
Last Update Posted: May 28, 2015
Last Verified: May 2015
Keywords provided by Enrico Finazzi Agro, University of Rome Tor Vergata:
BCG
hyaluronic acid
non-muscle invasive bladder cancer
non bacterial cystitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Poisoning
Chemically-Induced Disorders
Hyaluronic Acid
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents